Trump’s pick for next FDA chief is MD Anderson’s Stephen Hahn; reportsPresident Donald Trump plans to nominate leading oncologist Stephen Hahn as the new FDA commissioner, according to multiple Share XTrump’s pick for next FDA chief is MD Anderson’s Stephen Hahn; reportshttps://pharmaphorum.com/news/trumps-pick-for-next-fda-chief-is-cancer-specialist-stephen-hahn-reports/
Lawmaker weighs in on Gottlieb switch to industryScott Gottlieb has been urged by a senior Democrat to reconsider his swift move to join Pfizer’s board Share XLawmaker weighs in on Gottlieb switch to industryhttps://pharmaphorum.com/news/lawmaker-weighs-in-on-gottliebs-switch-from-fda-to-industry/
FDA announces further plans to hasten digital health R&DThe FDA has announced further details about its plans to hasten development of digital health products and tools. Share XFDA announces further plans to hasten digital health R&Dhttps://pharmaphorum.com/news/fda-announces-further-plans-to-hasten-digital-health-rd/
Gottlieb sets out vision for more transparent FDA, better rare disease guidanceThe FDA got a vote of confidence from the Trump administration when it recommended increasing its budget in Share XGottlieb sets out vision for more transparent FDA, better rare disease guidancehttps://pharmaphorum.com/news/gottlieb-sets-vision-transparent-fda-better-rare-disease-guidance/
Early approval: ‘science-based’ Gottlieb wins over scepticsAfter just seven months, Scott Gottlieb has stamped his own imprint on the FDA and, so far, has Share XEarly approval: ‘science-based’ Gottlieb wins over scepticshttps://pharmaphorum.com/views-and-analysis/early-approval-science-based-gottlieb-wins-sceptics/
Gottlieb would rather stay at FDA – and pharma would agreeAfter Tom Price reached for the ejector seat two weeks ago after a scandal involving private jet use, Share XGottlieb would rather stay at FDA – and pharma would agreehttps://pharmaphorum.com/news/gottlieb-rather-stay-fda-pharma-agree/
FDA’s Gottlieb vows to close orphan drug loopholesFDA commissioner Scott Gottlieb is continuing his plans to streamline and accelerate the regulators’ practices, but now plans Share XFDA’s Gottlieb vows to close orphan drug loopholeshttps://pharmaphorum.com/news/fdas-gottlieb-vows-close-orphan-drug-loopholes/
FDA rejects Amgen/UCB osteoporosis drugThe FDA has rejected Amgen and UCB’s Evenity (romosozumab) osteoporosis drug after a late-stage trial unexpectedly highlighted a Share XFDA rejects Amgen/UCB osteoporosis drughttps://pharmaphorum.com/news/fda-rejects-amgenucb-osteoporisis-drug/
FDA can help cut drug prices, says GottliebTrump’s FDA pick also vows to take on opioid addiction crisis Share XFDA can help cut drug prices, says Gottliebhttps://pharmaphorum.com/news/fda-drug-prices-scott-gottlieb/